Wegovy sales took a hit this year. Novo's CEO blames off-brand competition
Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy took a hit due to rising competition from off-brand, or ...
Zacks.com on MSN20h
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug
Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this ...
Resolutions from the Annual General Meeting of Novo Nordisk A/S
Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Helge Lund, chair of the Board of Directors ...